Valuation: Valneva SE Pref.

Market Cap 495M 557M 462M 422M 791M 53.64B 803M 5.59B 2.16B 27.36B 2.09B 2.04B 87.98B P/E 2026 *
-5.99x
P/E 2027 * 9.45x
Enterprise Value 629M 707M 587M 536M 1.01B 68.12B 1.02B 7.1B 2.75B 34.74B 2.65B 2.6B 112B EV / Sales 2026 *
4.16x
EV / Sales 2027 * 1.97x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 584M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.04%+1.97%+55.43%+154.28% 44.09B
Weighted average by Cap. +0.17%+1.83%+60.06%+145.78%

Financials

2026 *2027 *
Net sales 151M 170M 141M 129M 241M 16.36B 245M 1.7B 660M 8.34B 637M 623M 26.83B 283M 319M 265M 241M 453M 30.69B 460M 3.2B 1.24B 15.66B 1.2B 1.17B 50.35B
Net income -81.11M -91.18M -75.75M -69.11M -130M -8.79B -132M -916M -355M -4.48B -342M -335M -14.41B 53.07M 59.66M 49.56M 45.22M 84.83M 5.75B 86.08M 599M 232M 2.93B 224M 219M 9.43B
Net Debt 134M 150M 125M 114M 214M 14.48B 217M 1.51B 584M 7.39B 564M 552M 23.76B 62.48M 70.23M 58.35M 53.23M 99.86M 6.77B 101M 705M 273M 3.45B 264M 258M 11.1B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.710EUR
Average target price
6.193EUR
Spread / Average Target
+128.52%

Quarterly revenue - Rate of surprise